This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Malignant neoplasm of other and unspecified male genital organs, including Hilmo
C3_MALE_GENITAL_NAS_WIDE
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleonly males |
226754 |
2. Check conditionsNone |
226754 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
63 |
4. Check minimum number of eventsNone |
63 |
5. Include endpointsNone |
63 |
6. Filter based on genotype QC (FinnGen only) |
61 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of other and unspecified male genital organs, including Hilmo
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm, wide definition for exclusion
- Neoplasms
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded (different definition than used in FinnGen).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 61 | - | 61 |
| Unadjusted period prevalence (%) | 0.03 | - | 0.03 |
| Median age at first event (years) | 65.24 | - | 65.24 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 63
- Matched controls
- 630
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
19.8
18
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
17.5
16
*
130
Kela drug reimbursment
Malignant tumour
+∞
17.5
16
*
KFC00
NOMESCO Finland
Unilateral orchiectomy
227.9
17.4
17
*
C63.2
ICD-10 Finland
Malignant neoplasm: Scrotum
+∞
10.7
10
*
116
Kela drug reimbursment
Prostate cancer
+∞
10.7
10
*
C63.0
ICD-10 Finland
Malignant neoplasm: Epididymis
+∞
9.6
9
*
C63.9
ICD-10 Finland
Malignant neoplasm: Male genital organ, unspecified
+∞
9.6
9
*
WX408
NOMESCO Finland
General anesthesy, balanced
5.3
9.2
26
74
H02AB02
ATC
dexamethasone; systemic
58.4
9.0
10
*
NE1CG
NOMESCO Finland
Pelvic, hip and femur extensive MRI examination with high intensity magnet
+∞
8.5
8
*
N02AA05
ATC
oxycodone; systemic
5.8
8.4
19
44
D40.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Testis
90.3
7.6
8
*
L02AE02
ATC
leuprorelin; implant, parenteral
+∞
7.4
7
*
L02BB03
ATC
bicalutamide; oral
+∞
7.4
7
*
QBE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin of trunk
14.5
6.9
11
9
Z51.5
ICD-10 Finland
Palliative care
16.6
6.6
10
7
QX3HE
NOMESCO Finland
Ultrsound examination of lesion close to skin
77.4
6.6
7
*
B01AB10
ATC
tinzaparin; parenteral
10.3
6.4
12
14
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
6.3
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
19
42
6.05
8.82
4.6
1.9
217.63
242.51
u/l
0.73
19
37
24
94
3.51
5.15
4.0
2.4
—
—
—
0
0
33
170
2.98
4.34
4.4
2.9
—
—
—
0
0
19
72
3.35
4.20
3.9
2.4
1.65
1.28
e6/l
0.11
12
42
37
212
2.81
3.87
11.8
3.8
12.75
13.27
umol/l
0.11
37
200
24
116
2.73
3.41
5.0
2.5
0.96
0.41
e6/l
0.26
18
86
8
16
5.56
3.16
1.4
4.8
—
—
—
0
0
9
22
4.59
3.01
1.9
1.5
—
—
—
0
0
17
74
2.78
2.89
4.2
2.5
1.46
0.99
e6/l
—
10
43
12
44
3.13
2.72
24.8
23.1
112.83
123.59
g/l
1.11
12
44
32
194
2.32
2.70
19.0
9.0
1.17
1.20
mmol/l
1.12
32
172
27
153
2.34
2.65
5.1
2.8
—
—
—
0
0
14
58
2.82
2.59
21.9
18.3
0.39
1.33
mmol/l
0.37
14
46
37
242
2.28
2.57
25.5
18.8
1.58
1.41
inr
—
10
59
17
79
2.58
2.53
2.6
1.6
—
—
—
0
0
14
60
2.71
2.42
3.4
3.0
21.49
24.59
%
0.60
14
52
14
62
2.62
2.27
3.1
2.8
2.11
2.19
g/l
0.21
14
56
5
9
5.92
2.25
1.4
1.3
—
—
—
0
0
5
9
5.92
2.25
1.2
1.0
—
—
—
0
0
37
251
2.15
2.25
15.9
5.5
4.58
4.56
e9/l
0.01
32
219
9
32
3.11
2.10
1.8
1.7
—
—
—
0
0
39
280
2.03
1.93
12.3
6.5
6.92
6.97
mmol/l
0.05
39
264
5
12
4.42
1.86
2.4
1.7
253.80
238.17
%
—
5
12
5
13
4.08
1.75
2.4
1.7
84.40
81.31
%
—
5
13
5
13
4.08
1.75
1.6
1.1
—
—
—
0
0
14
73
2.18
1.59
3.5
2.6
11.22
13.86
umol/l
1.09
14
64
13
66
2.22
1.57
23.3
9.0
103.38
104.79
mmol/l
0.41
13
66
24
157
1.85
1.47
3.5
2.6
274.60
175.66
ug/l
0.38
24
143
43
337
1.87
1.46
13.4
5.2
80.49
73.75
u/l
0.78
43
310
11
54
2.26
1.43
2.8
1.7
—
—
—
0
0
11
56
2.17
1.31
2.6
1.6
—
—
—
0
0
16
96
1.89
1.25
6.9
3.5
48.31
150.50
ng/l
0.76
16
84
5
19
2.77
1.24
2.6
1.3
—
—
—
0
0
5
21
2.50
1.11
2.6
1.4
—
—
—
0
0
48
405
1.78
1.10
28.8
12.7
66.04
74.81
ml/min/173m2
1.60
38
326
44
365
1.68
1.05
42.7
15.8
14.97
14.57
%
0.20
44
358
6
30
2.10
0.89
1.3
1.5
—
—
—
0
0
6
31
2.03
0.87
5.8
5.2
78.82
110.60
ng/l
—
6
25
17
118
1.60
0.80
2.7
1.8
3.10
2.75
mg/l
0.33
17
97
9
57
1.67
0.75
5.0
3.4
5.63
5.84
kpa
—
9
52
9
57
1.67
0.75
5.0
3.4
-2.13
1.55
mmol/l
—
9
43
7
43
1.70
0.69
6.3
3.0
—
—
—
0
0
32
268
1.39
0.59
6.3
3.5
27.60
25.74
%
0.15
14
121
26
219
1.32
0.43
2.8
2.4
—
—
—
0
0
8
59
1.41
0.43
3.9
3.3
5.01
8.31
ug/l
—
8
51
0
15
0.00
0.42
0.0
1.2
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
0.15
—
0
6
0
17
0.00
0.41
0.0
1.0
—
—
—
0
0
19
223
0.79
0.31
3.9
3.9
45.85
72.91
ng/l
0.67
13
172
41
441
0.80
0.30
5.5
5.4
2.34
2.49
mmol/l
0.59
41
401
21
182
1.23
0.26
2.8
2.5
1.27
0.81
ug/l
0.24
16
122
49
464
1.25
0.24
43.7
18.3
139.69
139.65
mmol/l
0.02
49
449
13
107
1.27
0.24
2.2
1.8
553846488.54
390.59
pmol/l
0.47
13
85
8
103
0.74
0.23
2.9
1.9
1205.53
1258.13
nmol/l
—
8
79
49
465
1.24
0.23
44.7
18.3
4.01
4.04
mmol/l
0.39
49
449
51
486
1.26
0.23
49.1
20.1
129.08
140.00
g/l
3.14
51
475
0
10
0.00
0.21
0.0
1.8
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
41
431
0.86
0.16
4.7
4.8
6.02
6.17
mmol/l
0.55
41
379
15
160
0.92
0.05
4.7
3.4
—
—
—
0
0
48
471
1.08
0.03
17.2
8.9
30.40
26.76
u/l
0.68
48
443
28
273
1.05
0.01
2.7
3.1
110.79
54.90
u/l
0.35
28
246
20
201
0.99
0.00
2.5
1.9
92.64
91.86
pmol/l
0.02
11
118
41
412
0.99
0.00
5.9
6.9
40.11
41.44
mmol/mol
0.51
41
378
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
1.48
—
0
5
Mortality – FinRegistry
↥This endpoint is excluded (different definition than used in FinnGen).
Relationships between endpoints
↥Index endpoint: C3_MALE_GENITAL_NAS_WIDE – Malignant neoplasm of other and unspecified male genital organs, including Hilmo
GWS hits: -
This endpoint is excluded (different definition than used in FinnGen).